Spots Global Cancer Trial Database for patritumab deruxtecan

Every month we try and update this database with for patritumab deruxtecan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd	NCT06298084	Breast Cancer M... HER2-positive M... HER2 Low Breast... Advanced Breast...	Patritumab deru... Olaparib	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy	NCT05338970	Nonsquamous Non... EGFR L858R EGFR Exon 19 De...	Patritumab Deru... Platinum-based ...	18 Years -	Daiichi Sankyo
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	NCT06172478	Advanced Solid ... Melanoma Head and Neck C... Gastric Cancer Ovarian Carcino... Cervical Cancer Endometrial Can... Bladder Cancer Esophageal Canc... Pancreatic Carc... Prostate Cancer	HER3-DXd	18 Years -	Daiichi Sankyo
HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy	NCT05338970	Nonsquamous Non... EGFR L858R EGFR Exon 19 De...	Patritumab Deru... Platinum-based ...	18 Years -	Daiichi Sankyo
Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd	NCT06298084	Breast Cancer M... HER2-positive M... HER2 Low Breast... Advanced Breast...	Patritumab deru... Olaparib	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer	NCT04479436	Metastatic Colo...	Patritumab Deru...	18 Years - 100 Years	Daiichi Sankyo
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial	NCT05569811	Breast Cancer	Patritumab deru... Chemotherapy Letrozole	18 Years -	SOLTI Breast Cancer Research Group
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer	NCT04619004	Non-Small Cell ... Non-Small Cell ...	Patritumab Deru... Patritumab Deru...	18 Years -	Daiichi Sankyo
NeoadjuVAnt muLti-agENT Chemotherapy or Patritumab Deruxtecan With or Without endocrINE Therapy for High-risk HR+/HER2- Breast Cancer - VALENTINE Trial	NCT05569811	Breast Cancer	Patritumab deru... Chemotherapy Letrozole	18 Years -	SOLTI Breast Cancer Research Group
A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer	NCT04479436	Metastatic Colo...	Patritumab Deru...	18 Years - 100 Years	Daiichi Sankyo
HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease	NCT05865990	Metastatic Brea... Advanced Non-Sm... Solid Tumor, Ad...	Patritumab deru...	18 Years -	MedSIR
Patritumab Deruxtecan (U3-1402) in Unresectable Locally Advanced or Metastatic Breast Cancer	NCT04965766	Metastatic Brea...	U3-1402	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: